Thomas Dick’s lab is focused on the discovery of new preclinical development compounds against tuberculosis and non-tuberculous mycobacterial lung disease, including Mycobacterium abscessus and Mycobacterium avium. The lab looked at the use of β-lactams, specifically imipenem and cefoxitin, in the treatment of Mycobacterium abscessus lung disease, and the potential to improve their clinical utility by combining them with the recently approved durlobactam-sulbactam pair. Adding the FDA-approved durlobactam-sulbactam combination to the standard-of-care β-lactam antibiotics imipenem and cefoxitin can significantly improve their potency and bactericidal activity against Mycobacterium abscessus, potentially offering significant short-term benefits for treating this difficult-to-treat infection.
Negatu DA, Aragaw WW, Gebresilase TT, Paruchuri S, Kaya F, Shin SJ, Sander P, Dartois V, Dick T. Durlobactam to boost the clinical utility of standard of care β-lactams against Mycobacterium abscessus lung disease. Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0104624. doi: 10.1128/aac.01046-24. Epub 2024 Nov 20. PMID: 39565116; PMCID: PMC11784023. https://journals.asm.org/doi/10.1128/aac.01046-24
تعليقات